Revelation Biosciences Receives FDA Approval for Gemini in Kidney Disease Treatment

Revelation Biosciences Advances Kidney Disease Treatment with FDA Approval

Revelation Biosciences, Inc. achieves a significant milestone by receiving acceptance of its investigational new drug (IND) application for Gemini from the U.S. Food and Drug Administration (FDA). This approval enables the company to initiate a Phase 1b clinical study in the United States, aimed at evaluating Gemini as a preconditioning treatment for patients suffering from chronic kidney disease (CKD). The upcoming study is designed as a multi-site, placebo-controlled trial, which will involve the enrollment of up to 40 subjects across five different cohorts. The primary focus of the study is to assess the safety and tolerability of a single dose of Gemini, with secondary objectives that include evaluating pharmacokinetics and the ability of Gemini to modulate the innate immune response through various predictive biomarkers.

Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), administered intravenously. Previous preclinical studies and earlier Phase 1 trials have shown promising results, as Gemini met its primary safety endpoints while demonstrating significant pharmacodynamic activity through changes in biomarkers. The implications of this new trial are notable, as successful outcomes could lead to a Phase 2 study aimed at reducing the incidence, duration, and severity of acute kidney injury (AKI) in patients undergoing coronary artery bypass graft (CABG) or cardiac valve surgery. This potential represents a crucial advancement in the treatment options available for CKD patients, who often face serious health challenges.

James Rolke, CEO of Revelation, expresses pride in reaching this key milestone, highlighting the company's commitment to improving patient outcomes by leveraging the unique properties of trained immunity. The development of Gemini is part of a broader strategy encompassing multiple programs designed to prevent or mitigate acute kidney injury, post-surgical infections, and slow the progression of chronic kidney disease. The initiation of the Phase 1b study marks a critical step in the company's mission to provide innovative therapies that address significant unmet medical needs in renal health.

In related news, Revelation Biosciences continues to focus on the potential of trained immunity in treating various diseases. The company's commitment to research and development positions it as a key player in the life sciences sector, especially in terms of addressing chronic conditions that impact patient quality of life. As the clinical study progresses, stakeholders will be keenly watching for outcomes that could redefine treatment paradigms in kidney health.